Assertio Holdings, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Product sales, net
Commercialization agreement, net
Royalties and milestones
Royalty revenue
Other revenue
Total revenues

Costs and expenses:
Cost of sales
Research and development expenses
Selling, general and administrative expenses
Change in fair value of contingent consideration
Amortization of intangible assets
Loss on impairment of goodwill
Loss on impairment of intangible assets
Impairment of intangible assets
Restructuring charges
Total costs and expenses

Loss from operations
Other (expense) income:
Debt related expenses
Other gain (loss)
Gain (loss) on sale
Loss on debt extinguishment
Loss on Assertio Therapeutics divestiture
Interest expense
Interest income
Other gain, net
Total other (expense) income

Net loss before income taxes
Income tax expense
Net loss and comprehensive loss
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)

Comments